STTK - CONSENSUS CO - Shattuck Labs, Inc.

Shattuck Labs, Inc. (STTK) relies on external financing as it remains in the testing phase of its immune therapies. A team of leading oncologists is working to save lives, utilizing generous research budgets. Growth prospects depend on new partnerships and phase II trials, with the metric standing at 15.19. The market price visualization on GURU.Markets demonstrates the price action of this biopharmaceutical asset.

To isolate the fundamental stability of Shattuck Labs, Inc. (STTK) from market noise, the average target share price from leading investment houses is used, which currently stands at 15.19. By analyzing the history of analyst targets, an investor determines the convergence point of the price with the forecast, which is critically important for Shattuck Labs, Inc. (STTK) amid fierce competition with biotech startups and global pharma behemoths for leadership in immuno-oncology.